U.S. stock futures were higher this morning, with the Dow futures gaining more than 100 points on Monday.Shares of Inventiva ADR (NASDAQ: IVA) fell sharply in today's pre-market trading following H1 results.Inventiva reported losses of $(1.84) per share compared to the analyst consensus estimate of loss of 41 cents per share. The company reported quarterly sales of $5.050 million which missed the analyst consensus estimate of $5.310 million.Inventiva shares dipped 5.5% to $5.72 in pre-market trading.Here ar ...

U.S. stock futures were higher this morning, with the Dow futures gaining more than 100 points on Monday.Shares of Inventiva ADR (NASDAQ: IVA) fell sharply in today's pre-market trading following H1 results.Inventiva reported losses of $(1.84) per share compared to the analyst consensus estimate of loss of 41 cents per share. The company reported quarterly sales of $5.050 million which missed the analyst consensus estimate of $5.310 million.Inventiva shares dipped 5.5% to $5.72 in pre-market trading.Here ar ...

The company's financial metrics indicate a challenging environment. With a price-to-earnings (P/E) ratio of approximately -1.46, Inventiva is experiencing negative earnings. The price-to-sales ratio of about 33.51 suggests that investors are paying $33.51 for every dollar of sales. Additionally, the enterprise value to sales ratio is approximately 28.92, reflecting the company's valuation relative to its sales. Inventiva's debt-to-equity ratio is about -0.51, indicating more liabilities than equity. The cur ...

Cash and cash equivalents at €146.7 million including €24.6 million in short-term deposits1 as of June 30, 2025Receipt of the gross proceeds of €115.6 million from the second tranche of the structured financing of up to €348 million2, following in particular the completion in April 2025 of enrolment of the Phase 3 clinical trial NATiV3 evaluating lanifibranor in patients with MASHCash runway currently planned until the end of the third quarter of 2026Revenues of €4.5 million recorded in the first half of 20 ...

Inventiva S.A. (NASDAQ: IVA) will release earnings results for the first half of the year, after the closing bell on Monday, Sept. 29.Analysts expect the Daix, France-based company to report H1 loss at 41 cents per share. Inventiva projects quarterly revenue of $5.31 million, according to data from Benzinga Pro.Inventiva is scheduled to host Analyst and Investor Event on Oct. 8.Shares of Inventiva rose 0.7% to close at $6.05 on Friday.Benzinga readers can access the latest analyst ratings on the Analyst Sto ...

Inventiva S.A. (NASDAQ: IVA) will release earnings results for the first half of the year, after the closing bell on Monday, Sept. 29.Analysts expect the Daix, France-based company to report H1 loss at 41 cents per share. Inventiva projects quarterly revenue of $5.31 million, according to data from Benzinga Pro.Inventiva is scheduled to host Analyst and Investor Event on Oct. 8.Shares of Inventiva rose 0.7% to close at $6.05 on Friday.Benzinga readers can access the latest analyst ratings on the Analyst Sto ...

A downtrend has been apparent in Inventiva S.A. Sponsored ADR (IVA) lately. While the stock has lost 5.4% over the past four weeks, it could witness a trend reversal as a hammer chart pattern was formed in its last trading session. This could mean that the bulls have been able to counteract the bears to help the stock find support.While the formation of a hammer pattern is a technical indication of nearing a bottom with potential exhaustion of selling pressure, rising optimism among Wall Street analysts abo ...

Program will include an update on the Company’s lead asset, lanifibranor, ahead of anticipated Phase 3 NATiV3 topline results in the second half of 2026Three renowned international experts and a patient representative will highlight key trends shaping the MASH treatment landscape Daix (France), New York City (New York, United States), September 24, 2025 – Inventiva (Euronext Paris and NASDAQ: IVA) (“Inventiva” or the “Company”), a clinical-stage biopharmaceutical company focused on the development of oral t ...

U.S. stock futures were mixed this morning, with the Dow futures falling around 100 points on Friday.Shares of RH RH fell sharply in pre-market trading after the company posted weaker-than-expected second-quarter results after Thursday's closing bell.RH reported quarterly earnings of $2.93 per share, which fell short of the analyst estimate of $3.20. Quarterly revenue came in at $899.15 million, which missed the Street estimate of $904.64 million.RH shares dipped 11.5% to $201.98 in the pre-market trading s ...

公司活动安排 - 公司领导层将参加H C Wainwright第27届全球投资会议 时间为2025年9月9日15:00 EDT或21:00 CEST 地点纽约[1] - 公司领导层将参加第8届Lyon Pôle Bourse论坛 时间为2025年9月23日 地点法国里昂[1] - 公司领导层将参加KBC生命科学会议 时间为2025年9月25日05:00 EDT或11:00 CEST 地点比利时布鲁塞尔[2] - 公司领导层将参加Stifel 2025虚拟心脏代谢论坛 时间为2025年9月30日09:30 EDT或15:30 CEST 形式线上[2] - 公司领导层将参加欧洲MIDCAP活动 时间为2025年9月30日至10月1日 地点法国巴黎[2] 公司业务聚焦 - 公司为临床阶段生物制药企业 专注于开发口服小分子疗法 治疗MASH及存在重大未满足医疗需求的疾病[2] - 公司核心产品lanifibranor为新型泛PPAR激动剂 目前处于NATiV3关键性3期临床试验阶段 针对成人MASH患者[2] 公司上市信息 - 公司在泛欧巴黎交易所B compartment上市 股票代码IVA ISIN代码FR0013233012[3] - 公司同时在美国纳斯达克全球市场上市 股票代码IVA[3]